上市企业：金嗓子（06896.HK）、华润医药（03320.HK）、远大医药（00512.HK）、华森制药 （002907）、桂林三金（002275）、贵州三力（603439）、江中药业（600750）、片仔癀（600436） 相关企业：湖南时代阳光药业股份有限公司、天津市医药集团有限公司、桂龙药业（安徽）有限公司、 力诺集团股份有限公司、津药达仁堂集团股份有限公司第六中药厂、西安碑林药业股份有限公司、雷允 上药业集团有限公司、贵州黄果树立爽药业有限公司、无锡济煜山禾药业股份有限公司、贵州宏宇药业 有限公司、广西金秀圣堂药业有限责任公司、郑州卓峰制药有限公司、江西南昌济生制药有限责任公 司、江西济民可信药业有限公司、太极集团重庆中药二厂有限公司、西安科力药业有限公司 关键词：咽喉中成药发展历程、咽喉中成药市场政策、咽喉中成药产业链图谱、咽喉中成药销售额、咽 喉中成药竞争格局、咽喉中成药发展趋势 一、概述 咽喉病主要是因为风热上攻兼肺胃热盛，或热毒蕴结、火毒内盛，或阴虚内热、虚火上炎所致，临床主 要表现为咽喉肿痛，声音嘶哑。而咽喉中成药是指以中药为主要原料，经过炮制、提取、制剂等工艺制 成，专门用于防治咽喉部疾 ...

Group 1 - The company's stock price dropped by 15.15% on August 12, reaching 4.2 HKD per share with a trading volume of 4.268 million HKD [1] - The company, Jin Sang Zi Holdings Limited, specializes in the pharmaceutical and food health industry, producing over 60 products including throat lozenges and health candies, with an annual production capacity of 5 billion throat lozenges and an annual output value of 1 billion [1] - The company has several international certifications and its market presence spans over 20 countries and regions, including the US, Canada, EU, Russia, Australia, and Southeast Asia [1] Group 2 - As of the 2024 annual report, the company's total operating revenue was 1.185 billion RMB and net profit was 319 million RMB [2] - A forecast for the mid-2025 report indicates a projected profit decrease of 37% year-on-year [3]

Group 1 - The 2025 China Brand Festival, themed "AI and Going Global," was held in Shenzhen from August 7 to 11, attracting over ten thousand participants from various sectors [1] - The festival featured a large opening ceremony, nine key events, fifty parallel forums, brand launch events, and eight master classes, creating a platform for interaction and sharing of brand development experiences [1] - Wang Yong, the festival's founder, emphasized that AI and going global are crucial for China's economic resilience in 2025, providing more momentum and certainty for the global economy [1] Group 2 - Dong Mingzhu, Chairman of Gree Electric Appliances, stated that a brand's value lies in earning respect through quality, technology, integrity, and innovation, rather than short-term profits [2] - Jiang Peizhen from Guangxi Jinsangzi Group highlighted that the AI wave presents a renewal opportunity for traditional brands, urging Chinese companies to leverage AI to become a force for good in the world [2] - Experts discussed the new paths for brand intelligence and internationalization, focusing on how AI can drive Chinese manufacturing to break cultural barriers and reconstruct international value chains [2]

Group 1 - The stock price of Jinsongzi (06896.HK) closed at 4.350 HKD on April 28, marking a 3.82% increase from the previous trading day and reaching a one-year high [1] - The net capital inflow for the day was 2.7694 million HKD, with 3.65548 million HKD flowing in and 886.09 thousand HKD flowing out [1] - Jinsongzi Holdings Group Limited is recognized as an outstanding technology enterprise in the national pharmaceutical industry, originally established as Liuzhou Candy Factory in March 1956 [1] Group 2 - The company focuses on the pharmaceutical and food health industries, with over sixty types of products including Jinsongzi throat lozenges and various traditional foods [2] - Jinsongzi throat lozenges are well-regarded for their effectiveness in relieving throat discomfort and have maintained a leading market share in their category, exporting to over twenty countries and regions [2] - The company has achieved multiple certifications, including GMP, HACCP, ISO9001:2000, and FDA, establishing itself as a trusted unit in quality and consumer satisfaction in China [2]